Q3 2022 Results
Company overview
Financial review
2022 priorities
Appendix
Financial performance
Innovation: Pipeline overview
Innovation: Clinical trials
Cardiovascular
Immunology
Neuroscience
Oncology
pelacarsen - ASO targeting Lp(a)
NCT04023552 Lp(a)HORIZON (CTQJ230A12301)
Indication
Phase
Patients
Primary
Outcome
Measures
Arms
Intervention
Target
Patients
Secondary prevention of cardiovascular events in patients with elevated
levels of lipoprotein(a)
Phase 3
8323
Time to the first occurrence of MACE (cardiovascular death, non-fatal MI,
non-fatal stroke and urgent coronary re-vascularization)
TQJ230 80 mg injected monthly subcutaneously or matched placebo
Patients with a history of Myocardial infarction or Ischemic Stroke, or a
clinically significant symptomatic Peripheral Artery Disease, and Lp(a)
≥ 70 mg/dL
2025
Read-out
Milestone(s)
Publication
TBD
50 Investor Relations | Q3 2022 Results
References
Abbreviations
Other
NOVARTIS | Reimagining MedicineView entire presentation